je.st
news
Genocea Commences Phase 2 Dose Optimization Trial For GEN-003 HSV-2 Immunotherapy
2014-07-30 09:52:30| drugdiscoveryonline Home Page
Genocea Biosciences, Inc. a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, recently announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2)
Tags: trial
phase
dose
optimization
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||